A 42-year-old man is brought to the emergency department by emergency medical services for continuous, generalized tonic-clonic seizure activity. His family states the seizure began 15 minutes ago and has not stopped. He has a history of epilepsy but has been nonadherent to his medications. Vital signs are normal except for a heart rate of 128/min. Fingerstick blood glucose is 110 mg/dL. Two large-bore peripheral intravenous lines are established. Assuming the patient's seizure activity continues unabated despite each successive treatment, arrange the following pharmacologic interventions in the correct evidence-based chronological sequence for the management of status epilepticus.
- 1Administer intravenous lorazepam
- 2Administer intravenous fosphenytoin
- 3Initiate intravenous propofol continuous infusion
- 4Initiate intravenous pentobarbital continuous infusion
Answer
The correct sequence of pharmacologic interventions for status epilepticus is: 1) Intravenous lorazepam, 2) Intravenous fosphenytoin, 3) Intravenous propofol continuous infusion, and 4) Intravenous pentobarbital continuous infusion.
The correct sequence reflects the evidence-based neurocritical care guidelines for convulsive status epilepticus. First, a rapid-acting benzodiazepine (intravenous lorazepam) is administered for acute termination. If seizures persist, a long-acting, non-sedating antiseizure medication (intravenous fosphenytoin) is given to gain control without requiring intubation. If the patient enters refractory status epilepticus, continuous anesthetic infusions (intravenous propofol) are initiated, which mandate mechanical ventilation. Finally, for super-refractory status epilepticus that fails propofol, high-dose barbiturate coma (intravenous pentobarbital) is employed, acknowledging its high risk of hemodynamic instability.
Step-by-Step Solution
Key Concept
The management of status epilepticus follows a strict step-wise algorithmic approach: initial stabilization with benzodiazepines (Phase I), followed by non-sedating antiseizure medications (Phase II), then continuous anesthetic infusions (Phase III), and finally agents for super-refractory cases (Phase IV).
Estimated Time:1m 30s